Schizophrenia News and Research

Latest Schizophrenia News and Research

Stimulating brain's nicotine receptors may eliminate side effects of Alzheimer's drug: Research

A team of neuroscientists has discovered important new information in the search for an effective treatment for Alzheimer's disease, the debilitating neurological disorder that afflicts more than 5.3 million Americans and is the sixth-leading cause of death in the United States. Hey-Kyoung Lee, associate professor in the University of Maryland Department of Biology, and her research team have shown that they may be able to eliminate debilitating side effects caused by a promising Alzheimer's drug by stimulating the brain's nicotine receptors.

14 Oct 2010

Genmab and Lundbeck enter agreement to develop antibody therapeutics

Genmab A/S announced today an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab's antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms.

13 Oct 2010

Infection during pregnancy linked to increased risk for neurodevelopmental disorders in fetus

A pregnant woman's immune response to viral infections may induce subtle neurological changes in the unborn child that can lead to an increased risk for neurodevelopmental disorders including schizophrenia and autism. Research published in the online journal mBio- provides new insights into how this may happen and suggests potential strategies for reducing this risk.

13 Oct 2010

Alkermes' VIVITROL medication for treatment of opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL(naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence, following opioid detoxification.

13 Oct 2010

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.

12 Oct 2010

NCQA recertifies Lilly's online Health Education Answers program

Lilly's Health Education Answers program, an interactive online health and wellness tool, has received Health Information Product Recertification from the National Committee for Quality Assurance (NCQA).

11 Oct 2010

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo.

11 Oct 2010

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

FDA issues CRL for AZ-004 NDA application

Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for AZ-004 (Staccato loxapine), submitted as Adusuve Staccato (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Takeda, Envoy enter three-year research alliance to develop schizophrenia drug

Takeda Pharmaceutical Company Limited, a global pharmaceutical company, and Envoy Therapeutics Inc., a recently formed drug discovery company, today announced that they have formed a three-year research alliance aimed at discovering drugs for schizophrenia that will have greater efficacy and safety compared to current therapies.

11 Oct 2010

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.

7 Oct 2010

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson's Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson's disease, as part of the Foundation's prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical benefits of ND0611 in advanced Parkinson's disease patients.

6 Oct 2010

Centre for Addiction and Mental Health selected as field trial sites for DSM-5 criteria

Toronto's Centre for Addiction and Mental Health (CAMH) has been selected as one of seven adult field trial sites in North America and the only site in Canada to test proposed diagnostic criteria for the American Psychiatric Association's (APA) fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM).

6 Oct 2010

Study may lend insight about hallucination mechanism in schizophrenia

Scripps Research Institute scientists have shown for the first time that the neurotransmitter serotonin uses a specialized signaling pathway to mediate biological functions that are distinct from the signaling pathways used by hallucinogenic substances. The new findings could have a profound effect on the development of new therapies for a number of disorders, including schizophrenia and depression.

6 Oct 2010

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010

Galapagos honored with 2010 EUROPEAN BIOTECHNICA AWARD

The Belgian biotech company Galapagos has won the 2010 EUROPEAN BIOTECHNICA AWARD. Galapagos thus secures the lion's share of the prize money totalling 75,000 euros, which is offered every year in the competition staged by Deutsche Messe AG and its partners. The award celebrates innovative European companies from the biotechnology sector and the life sciences.

5 Oct 2010

International conference on brain stimulation in psychiatry and neurology to be held October 7 and 8

Thirteen national and international experts in the field of Brain Stimulation in Psychiatry and Neurology will meet October 7 and 8 during a conference held at the Douglas Mental Health University Institute. They will present research findings and ground-breaking clinical applications concerning the use of brain stimulation techniques. New treatments still under development, such as transcranial magnetic stimulation, will also be discussed. Close to 150 participants are expected to take part in this conference.

5 Oct 2010

Researchers reveal ways to halt Rett Syndrome

In a study published today in the Journal, Proceedings of the National Academy of Sciences, an international team of researchers based in the U.S. and UK revealed that they were able to halt the potentially lethal, breath holding episodes associated with the neurological disease Rett syndrome.

5 Oct 2010

McGill University joins two leading Swiss research institutions to enhance neuroscience research

Building on its worldwide reputation as a leader in neuroscience research, McGill University today joined with two leading Swiss research institutions - the University of Zurich (UZH) and the Swiss Federal Institute of Technology (ETHZ) - to enhance neuroscience research in a host of areas, in fields that include pain therapy, Alzheimer's disease, synapse modelling and repair, neuroimmunology and genetic mechanisms of brain diseases.

5 Oct 2010

NIEHS awards grant to study environmental impact on genetic information

The National Institute of Environmental Health Sciences has awarded $2.27 million to Indiana University researcher Joseph Shaw for a five-year study of how the environment alters genetic information through mutation and natural selection.

5 Oct 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

Stimulating brain's nicotine receptors may eliminate side effects of Alzheimer's drug: Research

Genmab and Lundbeck enter agreement to develop antibody therapeutics

Infection during pregnancy linked to increased risk for neurodevelopmental disorders in fetus

Alkermes' VIVITROL medication for treatment of opioid dependence

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

NCQA recertifies Lilly's online Health Education Answers program

COU-AA-301 Phase 3 study demonstrates improvement in CRPC survival rate

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

FDA issues CRL for AZ-004 NDA application

Takeda, Envoy enter three-year research alliance to develop schizophrenia drug

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

NeuroDerm receives $1M grant for development of ND0611 dermal patch for Parkinson's disease

Centre for Addiction and Mental Health selected as field trial sites for DSM-5 criteria

Study may lend insight about hallucination mechanism in schizophrenia

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Galapagos honored with 2010 EUROPEAN BIOTECHNICA AWARD

International conference on brain stimulation in psychiatry and neurology to be held October 7 and 8

Researchers reveal ways to halt Rett Syndrome

McGill University joins two leading Swiss research institutions to enhance neuroscience research

NIEHS awards grant to study environmental impact on genetic information

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Schizophrenia News and Research

Latest Schizophrenia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in